SCHEMBL24933449

SCHEMBL24933449

NC(=O)c1cc(-c2ccc(OCC3COCC4(CC4)O3)cc2)c(C(F)(F)F)[nH]c1=O

nearest known ligand 0.34

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 4/20 0.34
HSD17B1 P14061 5/20 0.33
HSD17B2 P37059 5/20 0.33
PRKAB2 O43741 2/20 0.33
PRKAG1 P54619 2/20 0.33
PRKAA2 P54646 2/20 0.33
PRKAA1 Q13131 2/20 0.33
PRKAG3 Q9UGI9 2/20 0.33
PRKAG2 Q9UGJ0 2/20 0.33
PRKAB1 Q9Y478 2/20 0.33
PARP1 P09874 1/20 0.33
FFAR4 Q5NUL3 5/20 0.32
GPR84 Q9NQS5 1/20 0.30
PARP15 Q460N3 1/20 0.30
PARP10 Q53GL7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24933512 0.96 FFAR1 (0.36) FFAR1HSD17B1HSD17B2PRKAB2PRKAG1
SCHEMBL24933793 0.95 FFAR1 (0.33) FFAR1HSD17B1HSD17B2PRKAB2PRKAG1
SCHEMBL24933691 0.94 FFAR1 (0.33) FFAR1HSD17B1HSD17B2PRKAB2PRKAG1
SCHEMBL30240724 0.88 HSD17B1 (0.34) FFAR1HSD17B1HSD17B2PRKAB2PRKAG1
SCHEMBL30240741 0.88 HSD17B1 (0.34) FFAR1HSD17B1HSD17B2PRKAB2PRKAG1
SCHEMBL24933746 0.88 HSD17B1 (0.34) FFAR1HSD17B1HSD17B2PRKAB2PRKAG1
SCHEMBL24933331 0.88 HSD17B1 (0.34) FFAR1HSD17B1HSD17B2PRKAB2PRKAG1
SCHEMBL24933887 0.87 PARP1 (0.37) FFAR1HSD17B1HSD17B2PRKAB2PRKAG1
SCHEMBL24933303 0.87 HSD17B1 (0.33) FFAR1HSD17B1HSD17B2PRKAB2PRKAG1
SCHEMBL24933717 0.87 HSD17B1 (0.33) FFAR1HSD17B1HSD17B2PRKAB2PRKAG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP claimed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN claimed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO claimed
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP disclosed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed